
MTP
Healthcare · Biotechnology & Medical Research · $2.0M market cap
Latest report
Time not confirmed
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Mar 31, 2019
EPS trend, 90 days to now · 30-day revisions 0 up, 0 down
Beat estimates in 0 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Nov 30, 2022 | Time not confirmed | — | 0.00 | — |
| Sep 14, 2022 | Time not confirmed | — | 0.00 | — |
| Apr 26, 2022 | Time not confirmed | — | 0.00 | — |
| Dec 1, 2021 | Time not confirmed | — | 0.00 | — |
| Sep 17, 2021 | Time not confirmed | — | 0.00 | — |
| Apr 30, 2021 | Time not confirmed | — | -0.03 | — |
| Mar 31, 2021 | Time not confirmed | 0.00 | -0.03 | — |
| Dec 2, 2020 | Time not confirmed | — | -0.06 | — |
| Sep 10, 2020 | Time not confirmed | — | -0.05 | — |
| Jun 3, 2020 | Time not confirmed | -1.30 | -0.40 | +69.6% |
| Mar 31, 2020 | Time not confirmed | 0.00 | -0.40 | — |
| Nov 27, 2019 | Time not confirmed | -0.03 | 0.00 | +100.0% |
| Sep 30, 2019 | Time not confirmed | -0.05 | 0.00 | +100.0% |
Biodexa Pharmaceuticals Plc, a drug delivery technology company, focuses on the research and development of medicines in the United Kingdom, rest of Europe, and internationally. The company is developing MTX110, a direct delivery treatment for diffuse intrinsic pontine glioma, medulloblastomas, and glioblastoma multiforme; MTX114, an immuno-suppressant for topical application in psoriasis; MTD211, a long-acting…
| Apr 24, 2019 |
| Before the open |
| -0.15 |
| -52.08 |
| -34620.0% |
| Nov 28, 2018 | Time not confirmed | -0.13 | -0.13 | 0.0% |
| Sep 27, 2018 | Time not confirmed | — | -64.07 | — |
| May 30, 2018 | Time not confirmed | — | 0.00 | — |